Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.10.22	Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022 (Businesswire)
13.10.22	Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older (Businesswire)
12.10.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age (Businesswire)
05.10.22	Pfizer Completes Acquisition of Global Blood Therapeutics (Businesswire)
04.10.22	Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial (Businesswire)
03.10.22	Pfizer Completes Acquisition of Biohaven Pharmaceuticals (Businesswire)
26.09.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age (Businesswire)
22.09.22	Pfizer Declares Fourth-Quarter 2022 Dividend (Businesswire)
22.09.22	Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries (Businesswire)
20.09.22	Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts (Businesswire)
19.09.22	Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union (Businesswire)
15.09.22	Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents (Businesswire)
14.09.22	Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022 (Businesswire)
14.09.22	Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine (Businesswire)
12.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union (Businesswire)
09.09.22	FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata (Businesswire)
07.09.22	FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women (Businesswire)
06.09.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
06.09.22	Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action (Businesswire)
01.09.22	Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences (Businesswire)
01.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union (Businesswire)
31.08.22	Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older (Businesswire)
25.08.22	Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate (Businesswire)
23.08.22	Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age (Businesswire)
22.08.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine (Businesswire)
19.08.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
12.08.22	Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants (Businesswire)
08.08.22	Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 (Businesswire)
08.08.22	Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology (Businesswire)
28.07.22	PFIZER REPORTS SECOND-QUARTER 2022 RESULTS (Businesswire)
27.07.22	General statement of acquisition of beneficial ownership (RSS)
30.06.22	Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™ (Businesswire)
29.06.22	Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine (Businesswire)
29.06.22	Statement of acquisition of beneficial ownership by individuals (RSS)
28.06.22	Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus (Businesswire)
28.06.22	Statement of acquisition of beneficial ownership by individuals (RSS)
25.06.22	Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron (Businesswire)
24.06.22	Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts (Businesswire)
23.06.22	Pfizer Declares Third-Quarter 2022 Dividend (Businesswire)
20.06.22	Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 (Businesswire)
17.06.22	Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age (Businesswire)
14.06.22	Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA (Businesswire)
09.06.22	Pfizer Completes Acquisition of ReViral (Businesswire)
09.06.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
08.06.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
06.06.22	Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S. (Businesswire)
04.06.22	Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer (Businesswire)
01.06.22	Pfizer Provides Update on Ownership Interest in Haleon (Businesswire)
31.05.22	Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability (Businesswire)
26.05.22	Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Pfizer Inc Cert.Deposito Arg.Repr. 0.5 Shs

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten